VANCOUVER, Wash., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI) ("Absci"), a data-first generative AI drug creation company, today announced the pricing of an underwritten public offering of 16,700,000 shares of its common stock at a public offering price of $4.50 per share, before deducting underwriting discounts and commissions. In addition, Absci has granted the underwriters a 30-day option to purchase up to an additional 2,505,000 shares of its common stock on the same terms and cond ...

VANCOUVER, Wash., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI) ("Absci"), a data-first generative AI drug creation company, announced today that it has commenced an underwritten public offering of $75.0 million of shares of its common stock. Absci also intends to grant the underwriters a 30-day option to purchase up to an additional $11.25 million of shares of its common stock. All of the shares in the proposed offering are to be sold by Absci. Absci intends to use the net proceeds from ...

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is Absci Corporation (ABSI) one of those stocks right now? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.Absci Corporation is a member of our Medical group, which includes 1073 different companies and currently sits at #7 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 i ...

Core Insights - Absci has appointed Sir Menelas "Mene" Pangalos to its Board of Directors and as co-chair of its Scientific Advisory Board, effective January 1, 2024, to enhance its AI-enabled drug discovery efforts [1][2] - Sir Pangalos brings over 25 years of experience in drug discovery and development, having previously served as Executive Vice President of BioPharmaceuticals R&D at AstraZeneca, where he significantly improved R&D productivity [1][2] - Absci's innovative 'zero-shot' generative AI model is positioned to reshape drug discovery, with recent collaborations including an AI-designed antibody for oncology and a partnership with Almirall for dermatological therapeutics [2] Company Overview - Absci is a generative AI drug creation company that integrates AI with scalable wet lab technologies to accelerate drug development and improve therapeutic outcomes [3] - The company's Integrated Drug Creation™ platform allows for the screening of billions of cells weekly, enabling rapid progression from AI-designed antibodies to wet lab-validated candidates in as little as six weeks [3] - Absci's headquarters is located in Vancouver, WA, with additional facilities in New York City and Zug, Switzerland [3]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to __________ Commission file number 001-40646 ABSCI CORPORATION (Exact name of registrant as specified in its charter) Delaware 85-3383487 (Sta ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to __________ Commission file number 001-40646 ABSCI CORPORATION (Exact name of registrant as specified in its charter) Delaware 85-3383487 (State or ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to __________ Commission file number 001-40646 ABSCI CORPORATION (Exact name of registrant as specified in its charter) Delaware 85-3383487 (State o ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to __________ Commission file number 001-40646 ABSCI CORPORATION (Exact name of registrant as specified in its charter) Delaware 85-3383487 (State or oth ...

Absci's Integrated Drug Creation Platform - Absci is developing an Integrated Drug Creation platform that combines proprietary wet-lab assays capable of generating billions of protein-protein interactions a week for machine learning (ML) training with a scalable wet-lab infrastructure capable of validating 2.8 million unique AI-generated designs a week[17] - Absci's platform aims to accelerate drug discovery by enabling de novo drug creation with 'zero-shot' generative AI, demonstrated across four therapeutic targets[31] - Absci's rapid cycle times allow for rapid iteration and improvement of AI models, reduction of preclinical development timelines, and increased probability of success[22, 24] AI-Driven Antibody Design and Optimization - Absci is the first to design and validate new antibodies with zero-shot generative AI[26] - Absci's AI model generated highly diverse and effective binders from a massive search space[35] - 85% of the top 100 "natural" Trastuzumab variants exhibit higher-affinity than wild-type[50] Novel Target Discovery and Bionic Protein Technology - Absci's workflow identifies antigens targeted by exceptional immune responses, with >6,600 reconstructed antibodies and >250 hits under evaluation[63] - Absci is advancing a high-yielding SoluPro platform that enables selective site-specific non-standard amino acid (nsAA) incorporation into difficult-to-produce biologics[68] Partnerships and Financial Position - Merck has invested $610 million in biobucks for Absci drug discovery pact[103] - Absci has >$180M of cash, cash equivalents and short-term investments[98]

Table of Contents | --- | --- | --- | --- | --- | --- | |----------------------------|-----------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------|-----------------------------------------------------------------------------------|------------------------------------------------------------------------------------|-------------------------------------------------------- ...